COMMUNIQUÉS West-GlobeNewswire

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
02/06/2025
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic [...]
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
02/06/2025
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
02/06/2025
Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 [...]
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
02/06/2025
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a [...]
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
02/06/2025
Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic biotechnology company [...]
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
02/06/2025
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today [...]
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test
02/06/2025
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium, 02 June 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics [...]
Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce
02/06/2025
Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé [...]
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02/06/2025
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic [...]
Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce
02/06/2025
Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé [...]
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02/06/2025
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic [...]
Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce
02/06/2025
Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé [...]
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02/06/2025
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic [...]
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
02/06/2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars [...]
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
02/06/2025
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S ( [...]
Ipsen S.A. - Lancement du programme de rachat d'actions
02/06/2025
Information réglementée Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés PARIS, FRANCE, 2 juin 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce ce [...]
Ipsen S.A. - Initiation of the share buy-back program
02/06/2025
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an [...]
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
02/06/2025
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus [...]
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
02/06/2025
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT [...]

Pages